Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer
Table 1
Baseline characteristics and clinically relevant variables of 107 study patients.
Variable
One-year survivors ()
One-year nonsurvivors ()
value
Age (yrs)
64.9 ± 13.1
62.9 ± 11.2
0.393
Male gender % ()
42.9% (24)
72.5% (37)
0.002
Body mass index (kg/m2)
22.8 ± 3.5
22.8 ± 3.0
0.986
History of smoking % ()
41.1% (23)
54.9% (28)
0.127
Hypertension % ()
54.9% (7)
23.5% (12)
0.135
Diabetes mellitus % ()
7.1% (4)
13.7% (7)
0.341
Red blood cell count (×106/dL)
4.1 ± 0.6
4.0 ± 0.7
0.514
White blood cell count (×103/dL)
7.30 ± 2.55
8.17 ± 3.48
0.135
Platelet count (×104/dL)
22.99 ± 8.91
25.59 ± 11.60
0.189
Creatinine (mg/dL)
1.06 ± 0.69
0.99 ± 0.43
0.487
AST (IU/L)
48.93 ± 26.66
43.55 ± 23.26
0.106
ALT (IU/L)
47.00 ± 22.74
40.65 ± 17.06
0.267
First-line adjunctive therapy % ()
Concurrent chemoradiotherapy
8.9% (5)
15.7% (8)
0.378
Traditional chemotherapy
50% (28)
66.7% (34)
0.116
Target therapy
41.1% (23)
17.6% (9)
0.011
Distant metastasis % ()
64.3% (36)
70.6% (36)
0.542
Stage % ()
1.000
IIIb
17.9% (10)
17.6% (9)
IV
82.1% (46)
82.3% (42)
Cell type % ()
0.134
squamous cell carcinoma
21.4% (12)
35.3% (18)
nonsquamous cell carcinoma
78.6% (44)
64.7% (33)
Metastatic site % ()
Pleura
16.1% (9)
23.5% (12)
0.336
Lung
19.6% (11)
21.6% (11)
0.813
Bone
32.1% (18)
21.4% (16)
1.000
Liver
3.6% (2)
17.6% (9)
0.023
Adrenal gland
0% (0)
2.0% (1)
0.468
Brain
10.7% (6)
23.5% (12)
0.075
First-line treatment status % ()
0.017
disease control
75.0% (42)
51.0% (26)
disease progression
25.0% (14)
49.0% (25)
Performance Status % ()
0.042
0
23.2% (13)
25.5% (13)
1
75.0% (42)
60.8% (31)
2
1.8% (1)
13.7% (7)
Charlson comorbidity index
6.8 ± 2.3
7.7 ± 1.9
0.027
Data expressed as mean ± SD or % () of patients. AST: aspartate aminotransferase; ALT: alanine aminotransferase.
